1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. FDA approves groundbreaking Alzheimer disease test

FDA approves groundbreaking Alzheimer disease test

A new test could be a game changer in diagnosing Alzheimer disease. The US FDA has approved the first in vitro diagnostic blood test to aid in identifying the condition.  

Why it matters: The test provides a more accessible method for detecting Alzheimer disease.

Who it's for: Adults aged 55 years and older who are showing signs or symptoms.

The Lumipulse G test detects amyloid plaques associated with Alzheimer disease using chemiluminescent enzyme immunoassay technology. This method offers high sensitivity and precision in biomarker quantification.

Go Deeper: Read the full FDA announcement.

Most Recent Content

  1. Stay engaged with advocacy at CAP26
  2. Podcast: Policy pressures shaping pathology's future
  3. CAP supports NJ legislation on pre-hospital blood transfusions
  4. Pathologist runs for Congress in Arkansas
  5. RESULTS Act surpasses 100 cosponsors
  6. View All